With new Alzheimer's pre­ven­tion tri­al, Roche and Genen­tech may put amy­loid hy­poth­e­sis to ul­ti­mate test

If the dozens of tri­als over the last two decades haven’t yield­ed a con­clu­sive re­sult, Roche and Genen­tech may soon fi­nal­ly put the amy­loid hy­poth­e­sis for Alzheimer’s to a fi­nal test.

The com­pa­nies an­nounced on Thurs­day a new tri­al to see whether their amy­loid-clear­ing an­ti­body gan­tenerum­ab can pre­vent cog­ni­tive de­cline in pa­tients who al­ready have plaque buildup in their brains but have yet to show mem­o­ry loss or oth­er cog­ni­tive symp­toms. The study will en­roll 1,200 pa­tients and fol­low them for four years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.